Although group 3 MBs exhibit some notable genomic features, such as specific aneuploidies and amplification of MYC, MYCN, or OTX2, the unresolved molecular heterogeneity of these tumors contributes to the low therapeutic success reported in patients [18, 29, 39]. Here, MYCN is linked to Mobius syndrome.